AR084019A1 - DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh - Google Patents

DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh

Info

Publication number
AR084019A1
AR084019A1 ARP110104423A ARP110104423A AR084019A1 AR 084019 A1 AR084019 A1 AR 084019A1 AR P110104423 A ARP110104423 A AR P110104423A AR P110104423 A ARP110104423 A AR P110104423A AR 084019 A1 AR084019 A1 AR 084019A1
Authority
AR
Argentina
Prior art keywords
alkyl
nitrile
substituents
cycloalkyl
independently selected
Prior art date
Application number
ARP110104423A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR084019A1 publication Critical patent/AR084019A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de acuerdo con la fórmula (1) son farmacológicamente efectivos como inhibidores del canal de potasio, en particular inhibidores de la corriente del canal de potasio rectificador de entrada operada por acetilcolina (es decir bloqueadores de IKACh) y se cree que son útiles en el tratamiento de arritmias cardíacas, en particular taquiarritmias supraventriculares, tales como fibrilación auricular y palpitación auricular.Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde cada R5 opcional se selecciona independientemente de fluoro, nitrilo, hidroxi, oxo, alquilo C1-5, cicloalquilo C3-5, alcoxi C1-5 o alcoxialquilo C1-5, en donde cualquier grupo alquilo, cicloalquilo o alcoxi está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro, nitrilo o hidroxi; R1 se selecciona de alquilo C1-6, cicloalquilo C3-6 o alcoxialquilo C1-6, en donde cualquier grupo alquilo, cicloalquilo o alcoxi está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro o nitrilo; R2 se selecciona de hidrógeno o alquilo C1-3; R3 se selecciona de alquilo C1-6, cicloalquilo C3-6 o alcoxialquilo C1-6, en donde cualquier grupo alquilo o cicloalquilo en estos sustituyentes está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro, nitrilo o hidroxi; cada R4 opcional se selecciona independientemente de halo, nitrilo, hidroxi, alquilo C1-3, alcoxi C1-3, alcoxialquilo C1-3 o alquil C1-3sulfuro, en donde cualquier grupo alquilo o alcoxi en estos sustituyentes está sustituido por 0, 1, 2 ó 3 sustituyentes que se seleccionan independientemente de halo, nitrilo o hidroxi; m se selecciona de 1, 2 ó 3; n se selecciona de 1 ó 2; x se selecciona de 0, 1, 2 ó 3; e y se selecciona de 0, 1, 2 ó 3.
ARP110104423A 2010-11-30 2011-11-29 DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh AR084019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41799610P 2010-11-30 2010-11-30

Publications (1)

Publication Number Publication Date
AR084019A1 true AR084019A1 (es) 2013-04-17

Family

ID=46162787

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104423A AR084019A1 (es) 2010-11-30 2011-11-29 DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh

Country Status (5)

Country Link
US (2) US8361998B2 (es)
AR (1) AR084019A1 (es)
TW (1) TW201249795A (es)
UY (1) UY33755A (es)
WO (1) WO2012074469A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
US20170258781A1 (en) * 2014-12-02 2017-09-14 Tufts Medical Center, Inc. Atrial specific antiarrhythmics for use in treating or preventing atrial fibrillation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7700M (es) * 1968-07-17 1970-02-23
FR2326179A1 (fr) * 1975-09-30 1977-04-29 Cerm Cent Europ Rech Mauvernay Nouveaux ethers de propanolamines utilisables dans le traitement des maladies cardiovasculaires
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
JPWO2004011430A1 (ja) 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
DE102004061017A1 (de) 2004-12-18 2006-06-22 Sanofi-Aventis Deutschland Gmbh Piperidinsulfonylharnstoffe und -thioharnstoffe, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
US20120142659A1 (en) 2012-06-07
UY33755A (es) 2012-06-29
US8361998B2 (en) 2013-01-29
TW201249795A (en) 2012-12-16
US20130143858A1 (en) 2013-06-06
WO2012074469A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
EA201691085A1 (ru) Замещенные бензамиды и способы их применения
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
CR20140301A (es) Derivados de betulina
MY180688A (en) New diazaspirocycloalkane and azaspirocycloalkane
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
BR112012026950A2 (pt) composto, e, uso de um composto
IN2014MN01521A (es)
UA110338C2 (en) Chemical compounds
UA108510C2 (en) Cyclopropane compound
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PH12014502413A1 (en) Cyclic bridgehead ether dgat1 inhibitors
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201690844A1 (ru) Ингибиторы gsk-3
MX2014011752A (es) Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
MA35086B1 (fr) Compose de triazolopyridine
ES2721623T3 (es) Procedimiento novedoso para la preparación de ceftarolina fosamil
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
UY33323A (es) Análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
AR084019A1 (es) DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh
CO6640201A2 (es) Moduladores de crth2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal